Stayble has submitted applications to regulatory authorities in The Netherlands for start of the Phase 2b clinical trial.
The company can announce that an important step for starting the phase 2b clinical trial during Q2 has been completed. The company has submitted applications to regulatory authorities and ethical committees in the Netherlands and previously in Russia, two out of three countries in which the Company's phase 2b study is planned to be conducted. Application to Spanish authorities is estimated during March.The primary goal of the phase 2b trial is to demonstrate safety, tolerability and a clinically relevant reduction in pain in patients. The study will include about 100 patients and will be